Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Ads

You May Also Like

Results of interventional study support the use of suPARnostic® Quick Triage in emergency departments

Press Release                                                                                                                                    Birkerød, 10 September 2018 Today, at the 12th European Congress of Emergency ...